BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guide

BFH772, supplied as SKU B6199, is a small-molecule VEGFR2 inhibitor for experiments that require targeted suppression of VEGFR2-mediated signaling. The BFH772 (VEGFR2 inhibitor) product dossier identifies the compound as 6-((6-(hydroxymethyl)pyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide, with CAS 890128-81-1, a molecular weight of 439.39 g/mol, and formula C23H16F3N3O3.

No directly matched paper evidence was supplied for this SKU. Accordingly, the guidance below separates product-dossier specifications from workflow recommendations and avoids assigning a cellular potency, dosing schedule, or assay outcome that has not been provided. The compound is best treated as a VEGFR2 signaling pathway inhibitor for controlled research rather than as a broadly active kinase reagent.

What This Product Solves

BFH772 addresses experiments in which VEGFR2 pathway activity must be perturbed while maintaining a defined kinase selectivity objective. The product description reports an IC₅₀ of 3 nM against VEGFR2. It also reports approximately 500-fold reduced potency against the listed related receptors FLK-1, FLT-1, and FLT-4, together with approximately 40-fold lower efficacy against B-RAF, RET, and TIE-2. These figures establish a product-dossier selectivity profile, but they do not replace a laboratory-specific kinase panel or cellular target-engagement control.

In practical terms, BFH772 can be evaluated as an angiogenesis inhibitor in VEGFR2-dependent models, including tumor angiogenesis research workflows. The dossier reports that oral administration inhibited tumor growth and angiogenesis in animal tumor models, but it does not provide study-specific dosing, exposure, statistical results, or model details here. Those observations should therefore be used as context for model selection, not as a substitute for a new in vivo protocol.

Formulation is the main operational constraint. BFH772 is insoluble in water but is reported to be soluble at concentrations of at least 53.4 mg/mL in DMSO and at least 15.33 mg/mL in ethanol. Aqueous assays must therefore account for solvent carryover, dilution-related precipitation, and matched vehicle controls. This makes the compound more appropriate as a selective anti-angiogenic agent for organic-solvent-compatible workflows than for protocols requiring direct water preparation.

For additional context, the internal article BFH772 (VEGFR2 Inhibitor): Technical Guidance and Protocol Parameters complements this section by emphasizing pathway specificity and solvent compatibility. The related BFH772 (VEGFR2 Inhibitor): Technical Use and Workflow Guide provides a parallel overview for tumor-model workflows and reinforces the limitation that the compound is not water soluble.

Protocol Parameters

• Assay: VEGFR2 kinase inhibition; Value: IC₅₀ 3 nM; Applicability: biochemical VEGFR2 assays and initial concentration-response planning; Rationale: provides the product-dossier benchmark for target potency, but should not be converted directly into a cellular working concentration; Basis: product specification in the product dossier.
• Assay: selectivity profiling; Value: approximately 500-fold reduced potency against the listed FLK-1, FLT-1, and FLT-4 receptors and approximately 40-fold lower efficacy against B-RAF, RET, and TIE-2; Applicability: orthogonal kinase controls and interpretation of pathway-specific results; Rationale: helps define an initial selectivity hypothesis, while exact assay conditions and panel composition require local verification; Basis: product specification.
• Assay: stock preparation; Value: solubility of at least 53.4 mg/mL in DMSO and at least 15.33 mg/mL in ethanol; Applicability: preparation of concentrated organic stocks before aqueous dilution; Rationale: select the solvent that is compatible with the assay and confirm that dilution does not cause visible precipitation; Basis: product specification.
• Assay: aqueous formulation check; Value: insoluble in water; Applicability: cell-based, enzyme, and ex vivo workflows using aqueous media; Rationale: direct addition of the solid to water is not an appropriate formulation strategy and may produce an unknown free concentration; Basis: product specification.
• Assay: storage and incoming QC; Value: store at -20 °C; purity above 96%; Applicability: lot release and routine reagent management; Rationale: retain the certificate of analysis and safety data sheet, and use the solid under the stated storage condition; Basis: product QC and storage information.

Workflow Setup and QC Checklist

Before the assay

1. Confirm the SKU, lot identity, certificate of analysis, safety data sheet, formula, and molecular weight before dispensing. Record the intended assay endpoint, such as biochemical VEGFR2 activity, a cellular pathway readout, or an angiogenesis-related phenotype.
2. Choose DMSO or ethanol only after checking compatibility with the assay system. Establish a vehicle-only control that receives the same solvent exposure as the BFH772 conditions. This is essential because solvent effects can resemble pathway inhibition or cytotoxicity.
3. Use the solid material stored at -20 °C and avoid relying on a prepared solution for long-term storage. Prepare working solutions close to the experiment, using clean, labeled containers and documented lot information.

During preparation and treatment

1. Dissolve BFH772 in the selected organic solvent before introducing it into aqueous buffer or culture medium. Mix until the preparation is visibly uniform, then dilute in a controlled manner. Inspect the final preparation for cloudiness, crystals, or settling.
2. Keep the solvent fraction consistent across all treatment conditions, including controls. If precipitation appears after dilution, do not interpret the nominal concentration as the active concentration; revise the dilution sequence or solvent strategy and repeat the preparation check.
3. Use a concentration-response design appropriate to the assay rather than importing the 3 nM biochemical IC₅₀ directly into cells or animals. Pair the primary readout with a viability, morphology, or assay-integrity measurement when the model permits.
4. For selectivity interpretation, include a pathway-independent control or orthogonal readout where feasible. A response that changes without evidence of VEGFR2 pathway involvement should not be assigned automatically to target-specific inhibition.

After the run

Document the solvent, stock preparation date, dilution sequence, visible formulation status, plate or batch identifiers, and any deviations. Retain raw data and control performance criteria. If the experiment is intended to model tumor angiogenesis, report the model, route, exposure design, and endpoint separately from the product-dossier statement that oral administration inhibited tumor growth and angiogenesis in animal models.

Common Failure Modes and Fixes

• Precipitation after dilution: The compound may exceed its practical solubility in the final aqueous environment. Recheck the solvent choice, dilution order, mixing, and final vehicle percentage. Exclude visibly precipitated wells from potency interpretation unless the assay was specifically designed to measure particulate material.
• Vehicle-associated assay effects: Unequal solvent exposure can create apparent differences between treatment groups. Normalize the vehicle across all relevant wells and include untreated and vehicle-only controls.
• Weak or inconsistent pathway response: A biochemical IC₅₀ does not guarantee the same cellular response. Check compound integrity, preparation clarity, assay dynamic range, target expression, endpoint timing, and whether the model is dependent on VEGFR2 signaling.
• Overinterpretation of selectivity: The reported fold differences are product-dossier values, not a complete kinase-wide characterization. Confirm important alternative targets with an orthogonal assay before assigning a phenotype exclusively to VEGFR2 inhibition.
• Loss of solution consistency: Long-term storage of solutions is not recommended. Prepare fresh working material for planned experiments and avoid carrying an old solution forward as though its concentration and activity were unchanged.

Scope and Limitations

BFH772 is suitable for research workflows focused on VEGFR2-mediated signaling, angiogenesis, and tumor-model hypothesis testing. It is not a good choice when the protocol requires water solubility, broad-spectrum kinase inhibition, or long-term storage of aqueous or organic solutions. The compound's reported selectivity should be treated as a starting point for experimental design, not proof that every observed phenotype is VEGFR2 dependent.

The available dossier also notes advancement into clinical studies for rosacea, but no clinical outcome, regimen, or trial result is provided here. That statement should not be used to infer efficacy in a separate indication or model. Likewise, the reported purity above 96% supports lot assessment but does not establish assay performance, cellular exposure, bioavailability, or in vivo tolerability in a user's system. All animal and cell experiments should follow applicable institutional approvals, chemical safety procedures, and model-specific controls.

Conclusion

BFH772 is a practical selective VEGFR2 kinase inhibitor for experiments that can accommodate DMSO or ethanol and require controlled modulation of angiogenesis-related signaling. Start with the dossier-defined potency, solubility, storage, and QC parameters; then validate formulation, vehicle tolerance, target dependence, and assay-specific response locally. Because no directly matched paper evidence was supplied, careful documentation and orthogonal controls are essential before extending results from a biochemical assay to cells or tumor models.